Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye.

Clearside’s patented microinjection dosage form is the only non-surgical method for focal administration of drugs to the retina and choroid through the suprachoroidal space (SCS™). As of early 2016, the company had products in Phase 2 and Phase 3 clinical trials and is developing additional therapies through collaborations with third parties.

An estimated 5 million Americans suffer from the various back-of-the-eye diseases that Clearside targets – namely, macular edema, non-infectious uveitis and wet AMD.